Cargando…

Matrix therapy is a cost-effective solution to reduce amputation risk and improve quality of life: pilot and case studies

Introduction: Chronic, non-healing ulcers remain one of the most challenging clinical situations for health care practitioners. Often, conventional treatments fail and lead to amputation, further decreasing the patient's quality of life and resulting in enormous medical expenditures for healthc...

Descripción completa

Detalles Bibliográficos
Autores principales: Desgranges, Pascal, Louissaint, Taina, Godeau, Bertrand, Barritault, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: EDP Sciences 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902838/
https://www.ncbi.nlm.nih.gov/pubmed/31821145
http://dx.doi.org/10.1051/rmr/190002
_version_ 1783477743098265600
author Desgranges, Pascal
Louissaint, Taina
Godeau, Bertrand
Barritault, Denis
author_facet Desgranges, Pascal
Louissaint, Taina
Godeau, Bertrand
Barritault, Denis
author_sort Desgranges, Pascal
collection PubMed
description Introduction: Chronic, non-healing ulcers remain one of the most challenging clinical situations for health care practitioners. Often, conventional treatments fail and lead to amputation, further decreasing the patient's quality of life and resulting in enormous medical expenditures for healthcare systems. Here we evaluated the use of and cost-effectiveness of the RGTA (ReGeneraTing Agents) medical device CACIPLIQ20 (OTR4120) for chronic lower-extremity ulcers in patients with Leriche and Fontaine Stage IV peripheral arterial disease who were not eligible for revascularization. Methods: This uncontrolled pilot study included 14 chronic lower extremity ulcers in 12 patients in one hospital. The pilot study included 12 patients with TcPO(2) < 20 mm Hg and ABPI < 0.5 who had either a minimum of one chronic lower extremity ulcer or a chronic ulcer related to amputation. OTR4120 was applied twice a week or until complete healing, for up to 12 weeks. Ulcer surface area reduction (%)after 2, 4, 8 and 12 weeks, appearance after 4 weeks, and healing after 12 weeks were measured and recorded. Results: A 35% reduction in ulcer size was achieved after 4 weeks. 7 (50%) out of 14 ulcers completely healed within 1 to 3 months of treatment. Discussion: OTR4120 is an effective therapeutic option for patients with chronic lower extremity ulcers, can provide major improvement of quality of life and has the added benefit of being a significant cost-effective solution for healthcare systems.
format Online
Article
Text
id pubmed-6902838
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher EDP Sciences
record_format MEDLINE/PubMed
spelling pubmed-69028382019-12-11 Matrix therapy is a cost-effective solution to reduce amputation risk and improve quality of life: pilot and case studies Desgranges, Pascal Louissaint, Taina Godeau, Bertrand Barritault, Denis Regen Med Res Original Article Introduction: Chronic, non-healing ulcers remain one of the most challenging clinical situations for health care practitioners. Often, conventional treatments fail and lead to amputation, further decreasing the patient's quality of life and resulting in enormous medical expenditures for healthcare systems. Here we evaluated the use of and cost-effectiveness of the RGTA (ReGeneraTing Agents) medical device CACIPLIQ20 (OTR4120) for chronic lower-extremity ulcers in patients with Leriche and Fontaine Stage IV peripheral arterial disease who were not eligible for revascularization. Methods: This uncontrolled pilot study included 14 chronic lower extremity ulcers in 12 patients in one hospital. The pilot study included 12 patients with TcPO(2) < 20 mm Hg and ABPI < 0.5 who had either a minimum of one chronic lower extremity ulcer or a chronic ulcer related to amputation. OTR4120 was applied twice a week or until complete healing, for up to 12 weeks. Ulcer surface area reduction (%)after 2, 4, 8 and 12 weeks, appearance after 4 weeks, and healing after 12 weeks were measured and recorded. Results: A 35% reduction in ulcer size was achieved after 4 weeks. 7 (50%) out of 14 ulcers completely healed within 1 to 3 months of treatment. Discussion: OTR4120 is an effective therapeutic option for patients with chronic lower extremity ulcers, can provide major improvement of quality of life and has the added benefit of being a significant cost-effective solution for healthcare systems. EDP Sciences 2019-12-10 /pmc/articles/PMC6902838/ /pubmed/31821145 http://dx.doi.org/10.1051/rmr/190002 Text en © P. Desgranges et al., published by EDP Sciences, 2019 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Desgranges, Pascal
Louissaint, Taina
Godeau, Bertrand
Barritault, Denis
Matrix therapy is a cost-effective solution to reduce amputation risk and improve quality of life: pilot and case studies
title Matrix therapy is a cost-effective solution to reduce amputation risk and improve quality of life: pilot and case studies
title_full Matrix therapy is a cost-effective solution to reduce amputation risk and improve quality of life: pilot and case studies
title_fullStr Matrix therapy is a cost-effective solution to reduce amputation risk and improve quality of life: pilot and case studies
title_full_unstemmed Matrix therapy is a cost-effective solution to reduce amputation risk and improve quality of life: pilot and case studies
title_short Matrix therapy is a cost-effective solution to reduce amputation risk and improve quality of life: pilot and case studies
title_sort matrix therapy is a cost-effective solution to reduce amputation risk and improve quality of life: pilot and case studies
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902838/
https://www.ncbi.nlm.nih.gov/pubmed/31821145
http://dx.doi.org/10.1051/rmr/190002
work_keys_str_mv AT desgrangespascal matrixtherapyisacosteffectivesolutiontoreduceamputationriskandimprovequalityoflifepilotandcasestudies
AT louissainttaina matrixtherapyisacosteffectivesolutiontoreduceamputationriskandimprovequalityoflifepilotandcasestudies
AT godeaubertrand matrixtherapyisacosteffectivesolutiontoreduceamputationriskandimprovequalityoflifepilotandcasestudies
AT barritaultdenis matrixtherapyisacosteffectivesolutiontoreduceamputationriskandimprovequalityoflifepilotandcasestudies